April 19, 2021
Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.
April 19, 2021
Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.
April 15, 2021
Managing patients with who progress on a TKI, the role of re-biopsy at progression of disease, and the future treatment landscape for ALK+ mNSCLC.
April 15, 2021
Approaching TKI (tyrosine kinase inhibitor)-based therapy for the first-line management of ALK+ mNSCLC.
April 15, 2021
Joshua M. Bauml, MD, presents the case of a 57-year-old man with ALK fusion+ non-small-cell lung cancer (NSCLC) and discusses recommended molecular tests to identify patients with molecular driver alterations.
April 15, 2021
Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.
April 14, 2021
Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.
April 14, 2021
An expert in ovarian cancer considers the future of ovarian cancer treatment, the use of PARP inhibitors and overcoming PARP resistance, and the emerging treatments options.
April 14, 2021
Erin Crane, MD, discusses the role of PARP inhibitors in the treatment of ovarian cancer.
April 14, 2021
Erin Crane, MD, provides an overview of the Phase 3 NOVA trial.